The third round of national collection is about to begin

Medical Network May 18 hearing the news broke, the third round with the amount of the purchase or will soon beginAccording to aspects of the industry news, the 15th Shanghai Pharmaceutical concentratedprocurement Services management meetings, meetings with the national Central purchasing mainly related to work-related, previously in charge of the national stakeholders involved in the work of the Central purchasing meetingSome analysts pointed out that the convening of the meeting could herald a new round Jicai has entered the preparatory stageBased on past experience, Jicai carry out general experience relevant departments held internal meetings, business seminars and other non-public sectors, after full discussion in the government and enterprise communications to enter the list of confirmed Jicai, formally part of public procurement tendersAnother industry source said, before the Shanghai meeting, the National Medical Insurance Bureau in Beijing has opened Jicai related meetings, it appears that the next stage will be to some enterprises or participationIn addition, the Shanghai conference also discussed the issues with the amount of consumables procurement, statistics now in the provinces, is expected before the third series of national Jicai will be included in some high-value consumables JicaiJust a few days ago Fujian and other provinces in the Central Purchasing documents for consumables have been published2020 according to the National Pharmaceutical strokes in the file, the relevant departments will strengthen over the conformance assessmentcompetition analysis, study and put forward suitable for centralized procurement of products with the amount of inventory and product characteristics analysisAs for the third round start time Jicai, former president of Zhejiang Guotai HongIndustry Association of blue cypress match analysis pointed out that the next batch with the amount of purchase will certainly be , originally expected in the first half it will begin, but because of the epidemic may be delayed for some timeaffected by the epidemic, with part of the second batch of selected varieties purchase amount supplied to delay for six monthsAccording to the Shanghai Sunshine Pharmaceutical Procurement Network April 10 published work suggests, influenced by the epidemic, 32 varieties selected in the second group of countries of Central Purchasing, olmesartan medoxomil tablets, tablets ambrisentan, polyethylene glycol 4000 powder, levocetirizine tablets four varieties exist at the beginning of the implementation of possible tight supply, delivery delays and other issues, olmesartan medoxomil is expected in June to gradually restore production capacity, the normal supplyNational Insurance Bureau had issued a document urging the provinces to do the second batch with the amount of ground work procurement bid results, the epidemic factors to consider, if successfulreally difficult to supply in April, can negotiate to defer supply but in no event later than JuneIf June was the second round of the Central Purchasing successful enterprises to resume product supply and procurement of the second round with the amount of time the successful outcome of the latest round landing, according to the previous law, landing on a comprehensive Jicai after the next round of the Central Purchasing may begin, the industry believes that perhaps July will start purchase amount from the first round with a 7 4 + 4 + 7 to expand around the country and then to a second round of Central Purchasing, Central Purchasing can be seen in advance the time interval is gradually shortened, the acceleration trend Jicai obvious round 4 + 7 2018 12 moon Jicai result, year February-March fall gradually; the first 6 months after purchasing 25 to expand around the country varieties; second round Jicai, January 2020 results released in April into the procurement phase Haitong Securities in a research report "compete in China - local multinational pharmaceutical companies and pharmaceutical companies contest" the analysis pointed out that the probability of a large amount of procurement was brought primarily sample Top100 selling drugs, and had a variety of manufacturers assessment, as indicated in accordance with Insurance Bureau, more popular varieties with possible inclusion in an amount of procurement; furthermore, may be incorporated with a variety of non-pharmaceutical Top100 selling purchase amount, and had a variety of manufacturers commentary Ping An Securities is expected to crown a new epidemic after the third round of the National Central Purchasing will start fast, too ≥3 family enterprise comment varieties included in probability who asked not to be named, the pharmaceutical industry to competition authorities had blue cypress, said the new round with the amount of purchases might push the boundaries of consistency evaluation, health insurance directory, medicines and supplies Guotai Hong expressed using large, high price, space is not a downward Jicai Jicai drugs may be incorporated In addition, for non-Medicare species Jicai also possible, but will not become the focus of the Central Purchasing Hai Tong Securities analysts pointed out that the company can see the number of successful varieties, with the amount of procurement resources to focus on domestic head Historical data proves that multinational pharmaceutical companies in the future to deal with the amount of purchases will become more active, to bring mature new round with the amount involved in drug procurement or multinational pharmaceutical companies will be the focus of the work at this stage Barring unforeseen circumstances, then, the match between the head of the domestic pharmaceutical companies and multinational pharmaceutical companies will be more intense.